Haier Biomedical absorbs and merges with Shanghai Laison, company responds: will consider the interests of small and medium investors

On December 23rd, Jin10 Data reported that Haier Biomedical and Shanghai Laisi are planning a stock-for-stock merger, in which Haier Biomedical will issue A-shares to all shareholders of Shanghai Laisi and raise funds through the issuance of A-shares. It is worth noting that Shanghai Laisi and Haier Biomedical have different trading permissions. Does this mean that the shareholders of Shanghai Laisi who are being merged can only choose to sell the shares after the stock-for-stock exchange? In response, when contacted as an investor, a Haier Biomedical staff member stated that it is currently just a preliminary indicative announcement and that further details are still under study. When asked about the option to receive cash, the staff member stated that they do not have relevant information and to refer to the announcement, but the company will consider the interests of small and medium-sized investors. In addition, the staff member mentioned that Haier Biomedical and Shanghai Laisi have synergy in business, research and development, and channels.